Intelligent Bio Solutions Financial Results
Intelligent Bio Solutions reported record fiscal first quarter 2027 revenue of $1.39 million, a 25% increase year-over-year, driven by higher-margin cartridge sales. The company also achieved a significant regulatory milestone by submitting its FDA 510(k) premarket notification for its fingerprinting drug screening system, targeting the U.S. market.
- Term
- Q1 2027
“Fiscal first quarter revenue was the highest quarterly revenue in our Company’s history. Each reader draws on a recurring supply of higher-margin cartridges, which is driving most of our revenue growth. Our business continues to scale with improving unit economics, including expanding gross profit margins driven by manufacturing efficiencies and a higher share of revenue from higher-margin cartridge consumables.”
Harry Simeonidis, President and CEO
“In September, we submitted our 510(k) premarket notification to the FDA for the Intelligent Fingerprinting Drug Screening System, the culmination of the clinical program we executed throughout 2026 and a key step toward our planned entry into the multi-billion-dollar U.S. drug screening market. Going forward, we will continue to invest in the clinical and regulatory work behind our 510(k) submission while maintaining discipline across the rest of the business.”
Harry Simeonidis, President and CEO